Cargando…

Real world experience of hypofractionated radical radiotherapy for non-small cell lung cancer (NSCLC) during the COVID-19 pandemic: a well-tolerated radiotherapy schedule with acceptable progression-free (PFS) and overall survival (OS)

Detalles Bibliográficos
Autores principales:	Jeyin, Nidhish, Kidane, Ghirmay, Withers, Dominic, Ball, Simon, Tarver, Kathryn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. Published by Elsevier B.V. 2023
Materias:	Radiotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123076/ http://dx.doi.org/10.1016/S0169-5002(23)00572-X

Ejemplares similares

EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates
por: Lancellotta, Valentina, et al.
Publicado: (2022)

P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
por: Oertel, Michael, et al.
Publicado: (2022)

P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
por: Oertel, Michael, et al.
Publicado: (2022)

Impact of COVID-19 on workload burden of a complex radiotherapy facility
por: Francolini, Giulio, et al.
Publicado: (2021)

A snapshot on radiotherapy for head and neck cancer patients during the COVID-19 pandemic: a survey of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) head and neck working group
por: De Felice, Francesca, et al.
Publicado: (2020)

Positional Accuracy of Treating Multiple Versus Single Vertebral Metastases With Stereotactic Body Radiotherapy
por: Chang, Joe H., et al.
Publicado: (2016)

Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer
por: Seppälä, Jan, et al.
Publicado: (2016)

Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis
por: Francolini, Giulio, et al.
Publicado: (2022)

Weekly hypofractionated radiation therapy in elderly non-resectable cutaneous squamous cell carcinoma of the head and neck region
por: De Felice, Francesca, et al.
Publicado: (2020)

Palliative radiotherapy indications during the COVID-19 pandemic and in future complex logistic settings: the NORMALITY model
por: Cellini, Francesco, et al.
Publicado: (2021)

ESTRO vision 2030: the young Italian Association of Radiotherapy and Clinical Oncology (yAIRO) commitment statement
por: De Felice, Francesca, et al.
Publicado: (2021)

Changes in Tumor Volumes and Spatial Locations Relative to Normal Tissues During Cervical Cancer Radiotherapy Assessed by Cone Beam Computed Tomography
por: Chen, Wenjuan, et al.
Publicado: (2017)

Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
por: Phelps, Lyndsey, et al.
Publicado: (2021)

The impact of particle radiotherapy on the functioning of cardiac implantable electronic devices: a systematic review of in vitro and in vivo studies according to PICO criteria
por: Barcellini, Amelia, et al.
Publicado: (2022)

P096: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’ s lymphoma.
por: Linderoth, Johan, et al.
Publicado: (2022)

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)
por: Francolini, Giulio, et al.
Publicado: (2022)

Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach
por: Boldrini, Luca, et al.
Publicado: (2018)

Uncertainties in estimating heart doses from 2D-tangential breast cancer radiotherapy
por: Lorenzen, Ebbe L., et al.
Publicado: (2016)

Dose and fractionation schedules in radiotherapy for non-small cell lung cancer
por: Kepka, Lucyna, et al.
Publicado: (2021)

30 day mortality in adult palliative radiotherapy – A retrospective population based study of 14,972 treatment episodes
por: Spencer, Katie, et al.
Publicado: (2015)

Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT)
por: Murray, Louise J., et al.
Publicado: (2014)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

Impact on mental health of the COVID-19 pandemic in a radiation oncology department
por: Caliandro, Morena, et al.
Publicado: (2022)

P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
por: Goldkuhl, Christina, et al.
Publicado: (2022)

P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
por: Oertel, Michael, et al.
Publicado: (2022)

P094: Long-term outcomes of bulky classic Hodgkin lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases
por: Kim, Jowon Laura, et al.
Publicado: (2022)

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

Magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) for oligometastatic patients: a single-center experience
por: Chiloiro, Giuditta, et al.
Publicado: (2023)

Pattern of care for re-irradiation in locally recurrent rectal cancer: a national survey on behalf of the AIRO gastrointestinal tumors study group
por: Mantello, Giovanna, et al.
Publicado: (2023)

Controversies in the role of radiotherapy in pleural mesothelioma
por: Hanna, Gerard G., et al.
Publicado: (2021)

Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy
por: Habermehl, Daniel, et al.
Publicado: (2013)

Radiotherapy in thoracic malignancies: the preface
por: Jassem, Jacek, et al.
Publicado: (2021)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Delivered dose can be a better predictor of rectal toxicity than planned dose in prostate radiotherapy
por: Shelley, L.E.A., et al.
Publicado: (2017)

Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment
por: Scaife, J E, et al.
Publicado: (2015)

Biological optimization for mediastinal lymphoma radiotherapy – a preliminary study
por: Rechner, Laura Ann, et al.
Publicado: (2020)

Functional imaging for radiotherapy treatment planning: current status and future directions—a review
por: Thorwarth, D
Publicado: (2015)

Radiotherapy for non-malignant disorders: state of the art and update of the evidence-based practice guidelines
por: Seegenschmiedt, M H, et al.
Publicado: (2015)

Long-term outcomes of the 2-week schedule of hypofractionated radiotherapy for recurrent hepatocellular carcinoma
por: Park, Jongmoo, et al.
Publicado: (2018)

Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer
por: Jain, Neeraj, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8dpi47qdl232kvfq79pd9d6eb9